Critical Point ranks 7 on the Humanoids 100 with a score of 87; YQ Bionics ranks 36 with 68. Critical Point is ahead on deployment, progress, technology, positioning, firepower and leverage. Level on production and commercials. Critical Point is based in Shanghai, China, YQ Bionics in Beijing, China. YQ Bionics: private. Critical Point is named in 30 signals and YQ Bionics in 0.
Critical Point develops and sells OmniHand dexterous robotic hands designed for humanoid platforms, including standard, Lite, and Ultra variants for manipulation and embodied-AI training.
Darker bar: ahead of the other company on that measure.
Critical Point (临界点) was established on 2026-01-14 as the spun-out dexterous hand business of Agibot (Zhiyuan Robotics), which holds 80 percent after contributing RMB 4 million at establishment. Within five months it had raised four rounds, crossed a USD 1 billion post-money valuation on 2026-06-24, delivered over 8,000 OmniHand units and over 10,000 grippers, ranked first in the Chinese dexterous hand market by shipments in Q1 2026, and turned operationally net profitable in Q1 2026, its first full quarter. Founder Xiong Kun graduated from the Hong Kong University of Science and Technology Robotics Institute, participated in the founding of Tencent Robotics X, worked at IDEA Research and Inovance, and joined Agibot in 2024 to lead the dexterous hand business. The flagship OmniHand 3 Ultra-M, launched at ICRA 2026 on 2026-06-02 as the fourth product in under five months, fits 20 active degrees of freedom into 189.5 by 88.5 by 40 millimetres at 630 grams using full direct drive, and the sensing is the differentiator: a miniature visuotactile sensor in each fingertip plus over 300 three-dimensional tactile sensing points across the palm, single-sensor force resolution around 0.005 N, spatial resolution around 0.04 millimetres and sensing density of 50,000 per square centimetre. The 8,000-unit installed base is what separates it from Yuansheng, also in this batch, which discloses none. The reservation is that most detail is company-sourced, no end customer is named, and the 80 p
30 signals name Critical Point.
42 facts on file.
YQ Bionics manufactures and supplies dexterous robotic hands, a manipulation component for humanoid robots.
Darker bar: ahead of the other company on that measure.
Yuequan Bionics builds dexterous robotic hands on a bionic "tension-compression body" architecture — closer to musculoskeletal loading than conventional linkage hands — and is one of the few hand makers actually in mass production: 36kr reports 10,000 units produced and orders exceeding RMB 100M, alongside financing rounds in the hundreds of millions of yuan (including a Pre-A+). Hands are the acknowledged bottleneck component of the humanoid industry, and a supplier shipping at this volume with real order book is a strategic node: every humanoid maker that does not build hands in-house is a potential customer. This is the strongest components story in the discovered queue.
21 facts on file.
Critical Point ranks 7 on the Humanoids 100 with a score of 87; YQ Bionics ranks 36 with 68. Critical Point is ahead on deployment, progress, technology, positioning, firepower and leverage. Level on production and commercials. Critical Point is based in Shanghai, China, YQ Bionics in Beijing, China. YQ Bionics: private. Critical Point is named in 30 signals and YQ Bionics in 0.
Critical Point ranks 7 on the Humanoids 100 with a score of 87; YQ Bionics ranks 36 with 68. Critical Point is ahead on deployment, progress, technology, positioning, firepower and leverage. Level on production and commercials. Critical Point is based in Shanghai, China, YQ Bionics in Beijing, China. YQ Bionics: private. Critical Point is named in 30 signals and YQ Bionics in 0. Both company files carry the scores on eight measures, the facts with sources and the latest signals.
Members see every signal and fact behind both companies, the live ranking, the questions the signals answer and the week explained. $99 a month, 7-day trial. What Frontier Tech Intelligence is →